Breast cancer has pioneered the use of the biomarker HER2, which is over-expressed in 10% to 25% of breast tumors causing tumor growth, through the stimulation of MAPK and PI3K/AKT signaling pathways, resulting in metastasis and, therefore, a poor prognosis for the patient. The gene discussed is ERBB2; the disease is breast carcinoma.